Skip to content
Parakho

Zydus Lifesciences Ltd

NSE ZYDUSLIFEBSE 532321

Q1 FY27, unaudited

Revenue
₹2,872.20 Cr
Profit after tax
₹339.60 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations2,872.20+10.97%11,484.00
Other income123.70−21.26%1,667.50
Total income2,995.90+9.12%13,151.50
Employee benefit expense561.40+15.23%1,966.20
Finance costs103.10−25.07%482.90
Depreciation & amortisation151.90+16.85%561.20
Total expenses2,540.20+11.88%8,602.70
Profit before tax455.70−4.04%4,381.90
Tax expense116.10+28.71%822.10
Profit after tax339.60−11.72%3,559.80
Total comprehensive income360.60−6.51%3,588.50
Earnings per share
Earnings per share, basic₹3.38₹35.38
Earnings per share, diluted₹3.38₹35.38

Q1 FY27 unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base unaudited, from the company’s filing with NSE. Source

FY26 unaudited, from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Zydus Lifesciences reported consolidated revenue of ₹271.5 billion for FY26, up 17% year-on-year, with EBITDA margin at 31.2% and net profit adjusted for exceptional items at ₹54.6 billion, up 15%. Q4 FY26 revenue was ₹75.9 billion, up 16% year-on-year, with EBITDA margin of 33.7% and adjusted net profit of ₹15.9 billion. Management discussed growth across US formulations, India branded formulations, international markets, consumer wellness and medical devices, along with the proposed acquisition of Assertio Holdings and other pipeline updates.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 104 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.